Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants
Clinical trial NCT04126213 · COMPLETED
Trial details
- NCT number
- NCT04126213
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-05
- Primary completion
- 2020-07-23
- Enrollment
- 534
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.